Q Line Biotech IPO Day 4: GMP ₹120 (₹-5)
Alright folks, we’re deep into the Q Line Biotech SME IPO on the NSE, and it’s Day 4! As of today, May 24th, 2026, the subscription numbers are still showing zero across the board for Retail, NII, and QIB categories. This is certainly an interesting development as we enter the final day of the IPO period, which wraps up on May 25th. Let’s dive into what this means.
| Date | GMP | Est. Listing |
|---|---|---|
| 28 May | +₹115 | ₹458 |
| 27 May | +₹100 | ₹443 |
| 26 May | +₹100 | ₹443 |
| 25 May | +₹120 | ₹463 |
| 23 May | +₹120 | ₹463 |
Subscription Status
Seeing 0x across all categories on Day 4 is a bit unusual, to say the least. Typically, by the final day, we’d expect to see some traction, especially in the Retail and NII segments. The absence of any subscriptions so far might indicate a few things. It could be that investors are waiting for the very last moment to apply, perhaps to gauge the final GMP or other market sentiments. Alternatively, it might suggest a lack of early interest, which could be a concern for the company. The Qualified Institutional Buyers (QIB) category also showing zero is notable. Usually, QIBs are early movers and their participation can often set the tone for the IPO. Their silence so far is something to watch closely. The lot size is 400 shares, with an issue price of ₹326 per share. The total subscription needs to be robust for a successful listing, and with just one day left, the pressure is definitely on.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 71.44x | |
| NII / HNI | 146.33x | |
| QIB | 123.94x | |
| Total | 102.49x |
| Date | Retail | NII | QIB | Total |
|---|---|---|---|---|
| 25 May | 71.44x | 146.33x | 123.94x | 102.49x |
| 22 May | 9.92x | 15.96x | 5.19x | 9.86x |
| 21 May | 3.61x | 5.24x | 4.15x | 4.11x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). The current GMP for Q Line Biotech stands at ₹120. This is a decrease of ₹5 from yesterday’s ₹125. While a ₹120 GMP is still positive and suggests a healthy listing gain, the slight dip is something to keep an eye on. Yesterday, the expected listing price was around ₹445 (₹326 + ₹119 GMP), and with the current GMP, it’s now hovering around ₹446 (₹326 + ₹120 GMP). This slight increase in the expected listing price despite the GMP decrease is interesting – it suggests the market might be factoring in other positive indicators or simply adjusting based on the overall IPO sentiment. However, a declining GMP, even by a small margin, can sometimes signal waning investor enthusiasm or a correction in expectations.
Should You Apply?
This is the million-dollar question, isn’t it? On one hand, the current GMP of ₹120 points towards a potentially profitable listing, with an expected listing price of ₹446. This represents a significant gain over the issue price of ₹326. However, the complete lack of subscription data on Day 4 is a significant red flag. It’s highly unusual and could mean either a last-minute surge or a lack of initial investor confidence. If you’re considering applying, it’s crucial to weigh these factors carefully. The SEBI advisor in us urges caution and due diligence. You’ll want to monitor the subscription numbers very closely on the final day. If there’s a substantial jump in subscriptions, especially from NIIs and Retail, it might be a good sign. Conversely, if it remains sluggish, it might be prudent to hold back. Remember, past performance and current GMP are indicators, not guarantees. Always do your own research and consider your risk appetite.